Drugnews

Why is BEQIA’s FDA goal date different from its possible U.S. launch date?

TAHO Pharmaceuticals’ apixaban oral film BEQIA had an FDA review goal date of April 22, 2027, as reported in Drugnews’s November 5, 2026 analysis. The BMS–Pfizer patent case is a separate constraint: a qualifying suit filed within 45 days of patent notice can stay final FDA approval for up to 30 months. Neither interval establishes BEQIA’s actual launch date.

Updated

Review and patent proceedings follow separate clocks
MeasureReported resultBasis
FDA review goalApril 22, 2027Company-announced target; not a launch commitment
Patent-litigation filing window45 daysAfter receipt of the relevant notice
Potential final-approval stayUp to 30 monthsSubject to statutory conditions and earlier terminating events

The original article’s spring 2029 stay-expiry estimate depends on the notice date and legal outcome. It is not an established stay-expiry or commercial launch date.

Sources

Read the full analysis

TAHO Doubles in Two Weeks, but a Court Holds Its US Clock — 2026-11-05